Intra-Cellular Therapies Inc.

NAS: ITCI

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders

/marketstate/country/us

Intra-Cellular Therapies Inc.

Market open

--Real time quotes

Jun 5, 2023, 1:44 p.m.

ITCI

/zigman2/quotes/209441868/composite

62.68

Change

+1.36 +2.22%

Volume

Volume 172,159

Real time quotes

/zigman2/quotes/209441868/composite

Previous close

$ 61.32

$ 62.68

Change

+1.36 +2.22%

Day low

Day high

$60.76

$63.12

52 week low

52 week high

$42.01

$66.56

Income Statement Balance Sheet Cash Flow Statement

Annual Financials for Intra-Cellular Therapies Inc.

View Ratios

Fiscal year is January-December. All values USD millions.	2018	2019	2020	2021	2022	5-year trend
Sales/Revenue	-	60,613	22.81M	83.8M	250.31M
Sales Growth	-	-	37,537.11%	267.35%	198.69%
Cost of Goods Sold (COGS) incl. D&A	368,673	477,121	1.9M	8.03M	20.44M
COGS excluding D&A	-	-	1.37M	7.5M	19.79M
Depreciation & Amortization Expense	368,673	477,121	528,118	533,360	656,000
Depreciation	368,673	477,121	528,118	533,360	656,000
Amortization of Intangibles	-	-	-	-	-
COGS Growth	-	29.42%	297.18%	323.98%	154.44%
Gross Income	(368,673)	(416,508)	20.92M	75.77M	229.87M
Gross Income Growth	-	-12.97%	5,122.22%	262.22%	203.39%
Gross Profit Margin	-	-	-	-	91.83%	NA

	2018	2019	2020	2021	2022	5-year trend
SG&A Expense	161.9M	153.6M	252.15M	361.46M	493.5M
Research & Development	132.17M	89.12M	65.78M	88.85M	134.72M
Other SG&A	29.73M	64.47M	186.36M	272.61M	358.78M
SGA Growth	-	-5.13%	64.16%	43.35%	36.53%
Other Operating Expense	-	-	-	-	-
Unusual Expense	-	-	-	-	-
EBIT after Unusual Expense	-	-	-	-	-
Non Operating Income/Expense	-	-	-	-	-
Non-Operating Interest Income	7.14M	6.29M	4.24M	1.57M	7.38M
Equity in Affiliates (Pretax)	-	-	-	-	-
Interest Expense	-	-	-	-	-
Interest Expense Growth	-	-	-	-	-
Gross Interest Expense	-	-	-	-	-
Interest Capitalized	-	-	-	-	-
Pretax Income	(155.13M)	(147.72M)	(226.99M)	(284.12M)	(256.25M)
Pretax Income Growth	-	4.77%	-53.66%	-25.17%	9.81%
Pretax Margin	-	-	-	-	-102.37%	NA
Income Tax	1,600	1,600	13,513	5,631	6,000
Income Tax - Current Domestic	5.06M	8.49M	40.06M	53.08M	52.8M
Income Tax - Current Foreign	-	-	-	-	-
Income Tax - Deferred Domestic	(5.05M)	(8.48M)	(40.05M)	(53.07M)	(52.79M)
Income Tax - Deferred Foreign	-	-	-	-	-
Income Tax Credits	-	-	-	-	-
Equity in Affiliates	-	-	-	-	-
Other After Tax Income (Expense)	-	-	-	-	-
Consolidated Net Income	(155.13M)	(147.72M)	(227.01M)	(284.13M)	(256.26M)
Minority Interest Expense	-	-	-	-	-
Net Income	(155.13M)	(147.72M)	(227.01M)	(284.13M)	(256.26M)
Net Income Growth	-	4.77%	-53.67%	-25.16%	9.81%
Net Margin Growth	-	-	-	-	-102.37%	NA
Extraordinaries & Discontinued Operations	-	-	-	-	-
Extra Items & Gain/Loss Sale Of Assets	-	-	-	-	-
Cumulative Effect - Accounting Chg	-	-	-	-	-
Discontinued Operations	-	-	-	-	-
Net Income After Extraordinaries	(155.13M)	(147.72M)	(227.01M)	(284.13M)	(256.26M)
Preferred Dividends	-	-	-	-	-
Net Income Available to Common	(155.13M)	(147.72M)	(227.01M)	(284.13M)	(256.26M)
EPS (Basic)	(2.84)	(2.68)	(3.23)	(3.50)	(2.72)
EPS (Basic) Growth	-	5.60%	-20.52%	-8.39%	22.08%
Basic Shares Outstanding	54.71M	55.19M	70.36M	81.25M	94.05M
EPS (Diluted)	(2.84)	(2.68)	(3.23)	(3.50)	(2.72)
EPS (Diluted) Growth	-	5.60%	-20.52%	-8.39%	22.08%
Diluted Shares Outstanding	54.71M	55.19M	70.36M	81.25M	94.05M
EBITDA	(161.9M)	(153.53M)	(230.7M)	(285.15M)	(262.97M)
EBITDA Growth	-	5.17%	-50.26%	-23.60%	7.78%
EBITDA Margin	-	-	-	-	-105.06%	NA

MarketWatch.com

Follow MarketWatch
RSS
Podcasts

Intraday Data provided by FACTSET and subject to terms of use. Historical and current end-of-day data provided by FACTSET. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.

Intra-Cellular Therapies Inc.

Annual Financials for Intra-Cellular Therapies Inc.

Latest News

dow

nasdaq

s&p 500

Kiosk